Beam Therapeutics Inc. (BEAM) Prices 5M Share Common Offering at $23.50/Sh

Beam Therapeutics Inc. (NASDAQ: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the pricing of its public offering of 5,000,000 shares of common stock at a public offering price of $23.50 per share. All of the shares are being offered by Beam Therapeutics. In addition, Beam Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock at the public offering price, less the underwriting discounts and commissions.

The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Beam Therapeutics, are expected to be approximately $117.5 million excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on October 5, 2020, subject to the satisfaction of customary closing conditions.

J.P. Morgan, Jefferies and Barclays are acting as joint book-running managers for the offering. Wedbush PacGrow is acting as lead manager for the offering.

You May Also Be Interested In

• Winnebago Industries refinances credit facility, extends maturity to 2031
• Nscale targets up to $3B in US IPO as soon as September - Bloomberg
• MAIA Biotechnology (MAIA) files $150M mixed shelf